Replies to post #258423 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

Intermittent dosing

Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease
Patent number: 10426754
Abstract: Composition and method for treatment of Alzheimer's disease that includes ANAVEX2-73. Method of treatment of Alzheimer's disease using pharmaceutical compositions comprising ANAVEX2-73 according to an intermittent dosage regimen.
Type: Grant
Filed: June 14, 2017
Date of Patent: October 1, 2019
Assignee: ANAVEX LIFE SCIENCES CORP.
Inventor: Marco Cecchi

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10426754.PN.&OS=PN/10426754&RS=PN/10426754

Good luck and GOD bless,

[nidan7500]

Curious, are these text examples from other (additional) A2-73 trials or are they older trials being reported in different manner?

It's all good. Need different eyes and minds involved as we wait. It is also notable that the text all say about the same thing.

If we get lots of new observers involved through expanded interests the pot starts to boil more. Good to see.

Assuming these are not from hypothetical examples.